A reader responds to "Seven pharmacotherapies do promote smoking abstinence at 6 and 12 months".
Talwar
Arunabh
A
Jain
Mukesh
M
Arora
Guljit
G
D000279:Administration, Cutaneous; D000280:Administration, Inhalation; D000284:Administration, Oral; D001552:Benzazepines / Q000627:therapeutic use; D016642:Bupropion / Q000627:therapeutic use; D002638:Chewing Gum; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D009538:Nicotine / Q000008:administration & dosage; D018722:Nicotinic Agonists / Q000008:administration & dosage*; D010349:Patient Compliance; D011336:Probability; D011792:Quebec; D011810:Quinoxalines / Q000627:therapeutic use; D018570:Risk Assessment; D012907:Smoking / Q000453:epidemiology; D016540:Smoking Cessation / Q000379:methods*; D000074606:Smoking Prevention; D014029:Tobacco Use Disorder / Q000517:prevention & control*; D016896:Treatment Outcome; D000068580:Varenicline
D001552:Benzazepines; D002638:Chewing Gum; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D009538:Nicotine; D000068580:Varenicline